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Abstract
Clinicians need more evidence-based medical guidance into which 
medications better treat patients predominantly experiencing a 
specific PTSD symptom cluster. Based on the review of 6 research 
articles, both venlafaxine and sertraline show statistically significant 
improvements in reexperiencing/intrusion PTSD symptoms when 
compared to baseline and placebo. These results are generalizable 
across a broad population due to the studies’ sample diversity. 
Furthermore, more research is needed into other SSRIs and SNRIs to 
treat other PTSD symptom clusters. 
Samantha Rodriguez, MMS (c)
Faculty Advisor:  Elizabeth Masten, MS, PA-C
Department of Medical Science
v Posttraumatic stress disorder (PTSD): mental health disorder 
precipitated by a traumatic experience and marked by symptom 
clusters of reexperiencing, avoidance, arousal/reactivity, and 
negative cognition/mood symptoms. 
v Patients with PTSD differ in symptoms experienced and 
responsiveness to PTSD medications.
v FDA-approved PTSD drugs = 2 selective serotonin reuptake 
inhibitors (SSRIs)
1. paroxetine (Paxil) 
2. sertraline (Zoloft)
v 60% of patients respond to treatment and <20-30% of the 
patients have complete symptom resolution.
v Selective norepinephrine reuptake inhibitor (SNRI) venlafaxine 
(Effexor) has been shown to reduce PTSD symptoms.
This is an evidence-based review of the efficacy of sertraline 
compared to venlafaxine in improving reexperiencing/intrusion 




Literature search in November 2019: 
“venlafaxine,” “PTSD,” “sertraline”
Inclusion criteria: sertraline or venlafaxine, ≥18 y/o, RCT,  PTSD 
Exclusion criteria: No individual investigation of intrusion/re-
experiencing symptoms, disorders other than PTSD, pooled 
analyses, No comparison of either sertraline & venlafaxine to each 
other or to placebo
6 research articles selected for review
Venlafaxine and sertraline are suggested as equally efficacious in 
treating patients with marked reexperiencing/intrusion symptoms 
based on PTSD symptom scales. 
Discussion Results 
Efficacy of Sertraline (Zoloft) Compared to Venlafaxine (Effexor) in 
Improving Reexperiencing/Intrusion Symptoms in Adults with PTSD
Venlafaxine and sertraline should be considered efficacious 
treatments for clinicians treating patients with pronounced 
reexperiencing/intrusion PTSD symptoms. These results are 
generalizable across a broad population due to the studies’ sample 
diversity. 
v FDA should consider venlafaxine a possible appropriate PTSD 
treatment and allocate more funds into researching its safety and 
efficacy profile. 
v More research is needed into other SSRIs and SNRIs to treat other 
PTSD symptom clusters. 
Conclusion
Note: *p=.005
Table 2. Summary of Results
Both venlafaxine and sertraline show statistically significant improvements in 
reexperiencing/intrusion PTSD symptoms when compared to baseline and placebo. One 
study found venlafaxine produced statistically significant improvements in 
reexperiencing/intrusion symptoms compared to placebo using one PTSD symptom scale, 
while sertraline did not. However, no other study showed either venlafaxine or sertraline 
was more efficacious than the other at reducing reexperiencing/intrusion symptoms based 
on PTSD symptom scales. 
Study Type of Drug Drug v. Baseline Drug v. Placebo Venlafaxine v. 
Sertraline
Davidson et al (2001) Sertraline NA S NA












Davidson, Baldwin, et al (2006) Venlafaxine ER NA S NA
Li et al (2017) Sertraline NA S NA
Panahi et al (2011) Sertraline NA S NA









S=Statistically Significant; NS=Not Statistically Significant; NA=Results Not Available; CAPS-
SX17=Clinician-Administered PTSD Scale; DTS=Davidson Trauma Scale
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Table 1. Comparison of Study Designs
Strengths Limitations
Double blinding Sample size
≥12 week treatment Study completion rate
Highly unlikely observer bias




Davidson et al 
(2001)
RCT 69 U.S. residents;
Both F & M




RCT 350 U.S residents; 





12 weeks CAPS-SX17, DTS
Davidson, 
Baldwin, et al 
(2006)
RCT 329 Residents of Argentina, 
Chile, Colombia, 
Denmark, Finland, 
Mexico, Norway, South 
Africa, Spain, Sweden, 
and the United Kingdom;
178 F, 151 M
Venlafaxine ER 75-200mg/d 24 weeks CAPS-SX17
Li et al (2017) RCT 65 Chinese residents;
9 F, 63 M (7 dropped out)
Sertraline 135mg/d 12 weeks IES-R
Panahi et al 
(2011)
RCT 70 Iranian veterans;
0 F, 70 M
Sertraline 50-200mg/d 10 weeks IES-R
Smajkic et al 
(2001)
RCT 32 Bosnian refugees; 







RCT=Randomized Control Trial; F=Female; M=Male; CAPS-2=Clinician-Administered PTSD Scale, part 2; CAPS-SX17=Clinician-
Administered PTSD Scale; DTS=Davidson Trauma Scale; IES-R=Impact of Event Scale-Revised; PSS=PTSD Symptoms Scale
